SSII vs DBVT vs ISRG vs ALKS vs JNJ

For growth investors, SS Innovations International, Inc.

(SSII) is the stronger pick with 105. 7% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Johnson & Johnson is actually cheaper at 19. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Intuitive Surgical, Inc. wins at 2. 01x versus Johnson & Johnson's 34. 17x.

Over the past 5 years, SS Innovations International, Inc.

(SSII) delivered a total return of +281. 6%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), SS Innovations International, Inc.

(SSII) is the lower-risk stock at 0. 01β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 8633% more volatile than SSII relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), SS Innovations International, Inc.

(SSII) is pulling ahead at 105. 7% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: SS Innovations International, Inc. grew EPS 40. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, SSII leads at 207. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -28. 5% for SS Innovations International, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -19. 2% for SSII. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Intuitive Surgical, Inc. (ISRG) is the more undervalued stock at a PEG of 2. 01x versus Johnson & Johnson's 34. 17x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Johnson & Johnson (JNJ) trades at 19. 2x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 24. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, JNJ (2.

2% yield) pays a dividend. SSII, DBVT, ISRG, ALKS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +132. 3% 10Y return). Both have compounded well over 10 years (JNJ: +132. 3%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SSII is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ISRG is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock; JNJ is a large-cap quality compounder stock. JNJ pays a dividend while SSII, DBVT, ISRG, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.